Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ibrahim Halil Halil Sahin"'
Autor:
Elaine Tan, Junmin Whiting, Christine Marie Walko, Todd C Knepper, Hao Xie, Iman Imanirad, Estrella M. Carballido, Seth Felder, Jessica M. Frakes, Qianxing Mo, Jennifer Permuth, Richard D. Kim, Daniel A. Anaya, Jason B. Fleming, Ibrahim Halil Halil Sahin
Publikováno v:
Journal of Clinical Oncology. 40:663-663
663 Background: GI malignancies continue to be a major cause of cancer related deaths, despite advances in therapy options. In pancreatic cancer, the presence of homologous recombination mutations (HRM) has been shown to confer increased sensitivity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e21bca7751c087496f22c62795af2cde
https://doi.org/10.1200/jco.2022.40.4_suppl.663
https://doi.org/10.1200/jco.2022.40.4_suppl.663
Autor:
Elaine Tan, Junmin Whiting, Hao Xie, Iman Imanirad, Estrella M. Carballido, Seth Felder, Jessica M. Frakes, Qianxing Mo, Christine Marie Walko, Jennifer Permuth, Richard D. Kim, Daniel A. Anaya, Jason B. Fleming, Ibrahim Halil Halil Sahin
Publikováno v:
Journal of Clinical Oncology. 40:174-174
174 Background: Colorectal cancer (CRC), while one of the most common cancer diagnoses, can behave heterogeneously based on molecular characteristics. A subset of patients (pts) with CRC are characterized with mismatch repair deficiency (MMR-d), thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2763aea5e052865fba6990d10a160540
https://doi.org/10.1200/jco.2022.40.4_suppl.174
https://doi.org/10.1200/jco.2022.40.4_suppl.174
Autor:
Gudbjorg Jonsdottir, Asgeir Thor Masson, Laura S. Jacobus, Michelle L. Churchman, Stephen B. Edge, Anne M. Noonan, Michael J. Cavnar, Susanna Varkey Ulahannan, Ibrahim Halil Halil Sahin, Carlos Hou Fai Chan
Publikováno v:
Journal of Clinical Oncology. 40:602-602
602 Background: Limited data is available regarding the effects of germline and somatic mutations in the homologous recombination repair (HRR) pathway in patients with resectable pancreatic cancer and exactly which mutations can be targeted with plat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78a456445e201610e05036bc23eddbe6
https://doi.org/10.1200/jco.2022.40.4_suppl.602
https://doi.org/10.1200/jco.2022.40.4_suppl.602
Autor:
Arvind Dasari, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Halil Sahin, Dustin A. Deming, Philip Agop Philip, Theodore S. Hong, Norman Wolmark, Greg Yothers, Thomas J. George, Christopher Hanyoung Lieu
Publikováno v:
Journal of Clinical Oncology. 40:TPS212-TPS212
TPS212 Background: Currently, there are no biomarkers validated prospectively in randomized studies for resected colon cancer (CC) to determine need for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) shed into the bloodstream repr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fdcfe1042f330a9e1c1820f3c59d5336
https://doi.org/10.1200/jco.2022.40.4_suppl.tps212
https://doi.org/10.1200/jco.2022.40.4_suppl.tps212